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Background: Small bowel stricture is one of the most common complications in patients with Crohn’s 
disease (CD). Endoscopic balloon dilatation (EBD) is a minimally invasive treatment intended to 
avoid surgery; however, whether EBD prevents subsequent surgery, remains unclear. We aimed to 
reveal the factors contributing to surgery in patients with small bowel stricture and the factors 
associated with subsequent surgery after initial EBD. 
Methods: Data were retrospectively collected from surgically untreated CD patients who developed 
symptomatic small bowel stricture after 2008 when the use of balloon-assisted enteroscopy and 
maintenance therapy with anti-tumor necrosis factor (TNF) became available. 
Results: A total of 305 cases from 32 tertiary referral centers were enrolled. Cumulative surgery-free 
survival was 74.0% at 1 year, 54.4% at 5 years, and 44.3% at 10 years. The factors associated with 
avoiding surgery were non-stricturing, non-penetrating disease at onset, mild severity of symptoms, 
successful EBD, stricture length <2 cm, and immunomodulator or anti-TNF added after onset of 
obstructive symptoms. In 95 cases with successful initial EBD, longer EBD interval were associated 
with lower risk of surgery. Receiver operating characteristic analysis revealed that an EBD interval of 
≤446 days predicted subsequent surgery, and the proportion of smokers was significantly high in 
patients who required frequent dilatation. 
Conclusions: In CD patients with symptomatic small bowel stricture, addition of immunomodulator 
or anti-TNF and smoking cessation may improve the outcome of symptomatic small bowel stricture, 
by avoiding frequent EBD and subsequent surgery after initial EBD. 
 
Keywords 




































































Conflicts of interest 
SB received lecture fees from AbbVie GK, Mitsubishi Tanabe Pharma Co., Ltd., Kyorin 
Pharmaceutical Co., Ltd., Janssen, Mochida Pharmaceutical, Nippon Kayaku, Zeria Pharmaceutical 
Co., Ltd., and EA Pharma Co., Ltd., and research support from AbbVie GK, and MSD Inc. RS received 
lecture fees from Mitsubishi Tanabe Pharma Co., Ltd., Janssen, AbbVie GK, EA Pharma Co., Ltd., 
and Nippon Kayaku. TF received research support from Eisai Co., Ltd., and Alfresa Co., Ltd., and 
lecture fees from AbbVie, Ajinomoto Pharma, Boehringer Ingelheim, Daiichi Sankyo Co., Ltd., EA 
Pharma Co., Ltd., Janssen, Kissei Pharmaceutical, Kyorin Pharmaceutical Co., Ltd., Kyowa Hakko 
Kirin, Mitsubishi Tanabe Pharma Co., Ltd., Mochida Pharmaceutical, Nippon Kayaku, and Zeria 
Pharmaceutical Co., Ltd. HS received research support from Bristol-Myers Squibb, AbbVie GK, MSD 
Inc., Daiichi Sankyo Co., Ltd., and Zeria Pharmaceutical Co., Ltd. SS received lecture fees from 
Mitsubishi Tanabe Pharma Co., Ltd., AbbVie GK, EA Pharma Co., Ltd., and Nippon Kayaku. HTan 
received lecture fees from JIMRO Co., Ltd., AbbVie GK, EA Pharma Co., Ltd., Mochida 
Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Co., Ltd. 
RO received lecture fees from AbbVie GK. KKa received lecture fees from Mitsubishi Tanabe Pharma 
Co., Ltd. and AbbVie GK. YS received lecture fees from Mitsubishi Tanabe Pharma Co., Ltd. and EA 
Pharma Co., Ltd. KKi received lecture fees from Mitsubishi Tanabe Pharma Co., Ltd., AbbVie GK, 
EA Pharma Co., Ltd., Janssen, Nippon Kayaku, and Olympus, and research support from AbbVie GK 
and Zeria Pharmaceutical. SA received lecture fees from Janssen, Mitsubishi Tanabe Pharma Co., Ltd., 
and JIMRO Co., Ltd. TKo received lecture fees from AbbVie GK, Ajinomoto Pharma, Asahi Kasei 
Medical, Astellas, Alfresa Pharma, Celltrion, EA Pharma Co., Ltd., Eisai Co., Ltd., Gilead Sciences, 
Janssen, JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku, Mochida 
Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Co., Ltd., and ZERIA 
Pharmaceutical Co., Ltd., and consulting fees from Alfresa Pharma, Covidien, Eli Lilly, Ferring 
Pharmaceuticals, Janssen, Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical, Nippon Kayaku, 
Pfizer, Takeda Pharmaceutical, and Thermo Scientific, and research support from EA Pharma Co., 
Ltd., Thermo Fisher Scientific, Alfresa Pharma, Nippon Kayaku, and Asahi Kasei Medical. AA 
received lecture fees from AbbVie GK, Mitsubishi Tanabe Pharma Co., Ltd., Kyorin Pharmaceutical 
Co., Ltd., Janssen, Astellas, Zeria Pharmaceutical, Miyarisan Pharmaceutical, Takeda Pharmaceutical, 
Bristol-Myers Squibb, Gilead Sciences, MSD Inc., and EA Pharma Co., Ltd., and research support 
from EA Pharma Co., Ltd., AbbVie GK, MSD Inc., and Mochida Pharmaceutical, and consulting fees 
from Mochida Pharmaceutical Co., Ltd., and Takeda Pharmaceutical. TH received lecture fees from 
Mitsubishi Tanabe Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., AbbVie GK, Janssen, JIMRO 
Co., Ltd., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical, Gilead 
Sciences, Celltrion, Nippon Kayaku, Kissei Pharmaceutical, Miyarisan Pharmaceutical, Zeria 


































































GK, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Co., Ltd., JIMRO Co., Ltd., EA Pharma Co., 
Ltd., Eli Lilly, Pfizer Japan Inc, Nichi-Iko Pharmaceutical, and Nippon Kayaku, and research support 
from EA Pharma, AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co. Ltd., and Otsuka 




































































Crohn’s disease (CD) is a chronic granulomatous inflammatory bowel disease condition characterized 
by skip lesions and transmural inflammation, and chronic inflammation may affect any part of the 
gastrointestinal tract. Fibrosis associated with the chronic inflammation eventually results in stricture 
or obstruction of the gastrointestinal tract. Lesions frequently develop in the ileum and colon, but 
strictures are more likely to develop in the small bowel than in the colon. Thus, CD patients undergo 
surgical treatment most commonly for small bowel stricture1.  
Treatment options for stricture in CD patients are: pharmacotherapy such as anti-tumor 
necrosis factor (anti-TNF) antibody or immunomodulator; endoscopic therapy, typically endoscopic 
balloon dilatation (EBD); and surgery including strictureplasty.2 The efficacy of pharmacotherapy for 
stricture in CD has not yet been established, and the effectiveness of, for example, anti-TNF antibody 
therapy, is not consistent, with it being effective in some studies3-6 but not in others.2, 7 Also, the role 
of immunomodulators for the treatment of stricturing complications in CD has been not explored 
directly8. It is pertinent to note that pharmacotherapy was effective in the treatment of inflammatory 
stricture.9  
The introduction of double-balloon enteroscopy in 200110 and of single-balloon enteroscopy 
in 200811 enabled EBD for small bowel stricture, as well as observation of small bowel lesions, using 
a balloon-assisted enteroscope. EBD has become an important therapeutic option for symptomatic 
stricture,12 but many previous studies on EBD in CD patients included heterogenous background 
factors such as the location of stricture (small bowel vs colon)13-15 and the cause of stricture (de novo 
vs anastomotic).13-16 Also, many were single-center studies, and as such the results were affected by 
treatment policy and expertise at individual centers. 
EBD is minimally invasive and offers a high success rate with a low frequency of procedural 


































































ultimately this reduces quality of life. Several studies have examined factor associated with avoiding 
the need for surgery by performing EBD,20-22 but clinical course and intestinal resection after EBD 
have rarely been investigated.  
In this study, we collected surgically untreated cases with CD who developed symptomatic 
small bowel stricture after 2008 when the use of balloon-assisted enteroscopy (BAE) and maintenance 
therapy with anti-TNF antibody became available. This study sought to reveal the factors contributing 
to intestinal resection in small bowel stricture in CD patients and the factors associated with outcomes 







































































This retrospective multicenter study was approved by the ethics committees of the participating 
institutions. The study is registered in the University Hospital Medical Network Clinical Trials 
Registry (UMIN000028355). 
 
Study methods and subjects 
One of the authors (S.B.) directly contacted gastroenterologists and surgeons at the participating 
institutions to ask them to report all cases of CD with symptomatic small bowel stricture and no 
previous history of intestinal surgery seen between January 2008 and December 2017. Data were 
collected retrospectively from 32 tertiary referral centers and submitted to Shiga University of Medical 
Science. Patients were screened using records in the participating institution’s databases, such as 
endoscopy filing systems and/or by retrieving the following ICD-10 codes from their medical history 
databases: K565 (Intestinal adhesion (bands) with obstruction (postprocedural) (postinfection)); K566 
(Other and unspecified intestinal obstruction); K567 (Ileus, unspecified); K500 (Crohn’s disease of 
small intestine); K501 (Crohn’s disease of large intestine); K508 (Crohn’s disease of both small and 
large intestine); K509 (Crohn’s disease, unspecified). For patients who were screened, their medical 
charts were individually reviewed to check whether they actually had obstructive symptoms and were 
eligible to participate in this study.  
The inclusion criteria for CD patients were a medical history from January 2008 to March 
2017, development of obstructive symptoms for the first time from January 2008 to March 2017, and 
confirmation of small bowel stenosis by imaging examinations such as BAE, small bowel follow-
through, CT, and MRI. Exclusion criteria were intestinal resection performed before the onset of 


































































participate in the study. Data were obtained according to a previously defined case report sheet by 
inflammatory bowel disease specialists or gastroenterologists. These data included a detailed report of 
the disease phenotype and history and the baseline status of CD according to the Montreal 
classification.23  
 
Endpoints and definitions 
The primary endpoint of this study was the cumulative intestinal resection rate after onset of 
obstructive symptoms. The secondary endpoint was the effectiveness of EBD and pharmacotherapy 
in relation to the cumulative intestinal resection rate. We also analyzed the factors associated with 
intestinal resection or EBD interval after initial EBD. In this study, the observation period was set 
from the first onset of obstructive symptoms to intestinal resection or censoring.  
For those patients who did not undergo endoscopy or whose entire small bowel could not be 
observed using BAE, the number of small bowel strictures was determined by imaging examinations 
such as CT, MRI, and small bowel follow-through. Given that involvement of the ileocecal valve at 
the stricture site may affect the actual procedure and eventual outcome of EBD, the stricture site was 
divided into two types, strictures with and without ileocecal valve involvement, which were defined 
as ileocecal valve and small intestinal strictures, respectively. When a patient had multiple strictures, 
the causative stricture was determined by the physician’s general assessment considering the degree 
of stricture and/or prestenotic dilatation. The scope of use was the colonoscope or BAE. When the 
EBD of the causative lesion was successful, it was defined as a successful EBD. The degree of 
prestenotic dilatation and the progress of symptoms after EBD were used to judge whether the stenosis 
was a causative lesion. If EBD was attempted but was technically difficult or impossible, the procedure 
was defined as unsuccessful.  


































































moderate (outpatient department visit required); and severe (intestinal obstruction, hospitalization 
required). Medical charts were investigated to evaluate the severity of symptoms. Mild symptoms 
were checked from symptom descriptions at the outpatient visit, moderate symptoms from irregular 




All statistical analyses were performed using Prism, version 8.01 (GraphPad, San Diego, CA), and 
JMP software, version 14.0 (SAS Institute, Cary, NC). The cumulative surgery-free survival rate was 
calculated using Kaplan-Meier analysis. The log-rank test was used to determine statistical differences 
between groups. Cox regression analysis was performed to estimate the risk of intestinal resection. 
Receiver operating characteristic (ROC) analysis was used to calculate the cutoff value of the EBD 
interval associated with intestinal resection by identifying the point closest to perfect differentiation. 
Logistic regression analysis was performed to determine the factors associated with EBD interval. 
After univariate analysis, all variables with P values less than 0.20 were considered in the subsequent 
multivariate analysis. We also refer to the literature for the selection of variables. P values were two-







































































A total of 348 patients from 32 centers were enrolled. After excluding patients who did not meet the 
inclusion criteria, the remaining 305 patients were entered into the overall analysis. Also, factors 
associated with intestinal resection after initial EBD and EBD interval were analyzed in 95 patients 
from 24 centers (Figure 1). The background characteristics of the all patients are shown in Table 1. A 
total of 129 patients required intestinal resection during the observation period. The indication for 
intestinal surgery was related to the causative strictures in all cases; 120 cases of small bowel stricture, 
6 cases of small bowel perforation, 1 case of abscess, and 2 cases of perforation as EBD complication. 
For examining strictures, colonoscopy or BAE was performed. Of 65 colonoscopies, 46 procedures 
were done using the conventional colonoscope, 8 were done using a thin colonoscope, and 11 were 
done using a long thin colonoscope. Of 181 BAEs, 93 procedures were done using a single-balloon 
enteroscope, and 88 procedures were done using a double-balloon enteroscope. The proportion of 
patients who underwent BAE was significantly higher among those patients who underwent EBD than 
those who did not undergo EBD. All procedures were done using a through-the-scope balloon dilator 
(CRETM balloon catheter; Boston Scientific Co., Natick, MA).  
 
Factors associated with intestinal resection in all patients 
Kaplan-Meier analysis revealed cumulative surgery-free survival at 1, 5, and 10 years after onset of 
obstructive symptoms was 74.0%, 54.4%, and 44.3%, respectively (Figure 2a). The log-rank test for 
each background factor showed that sex, disease location, disease behavior at onset, perianal lesion, 
and smoking status were not significant factors (Suppl. Figure 1a, b, c, d, e). Cumulative surgery-free 
survival was significantly higher in patients with mild obstructive symptoms (Figure 2b). Prognosis 


































































was lowest in patients who did not undergo endoscopy (Figure 2c, p <0.001, log-rank test), however, 
the choice of endoscope did not affect surgery in multivariate analysis (Table 2). Cumulative surgery-
free survival did not differ based on location of stricture (ileocecal valve or small intestine) or number 
of strictures (Suppl. Figure 1f, g), but it was significantly lower with stricture length ≥2 cm (Figure 
2d).  
 EBD was successful in 100 patients and was not successful in 32 patients due to technical 
difficulties (e.g., unreachable lesions), giving an EBD success rate of 75.5%. The cumulative surgery-
free survival was significantly high when EBD was successful; cumulative surgery-free survival at 1, 
5, and 10 years was 93.8%, 72.8%, and 62.9%, respectively (Figure 2e). This result was also confirmed 
when we limited the cohort to patients who underwent endoscopy (n = 246) with observation periods 
starting from the timing of endoscopy and not from occurrence of the first symptom (Figure 2f). 
Procedural complications were seen in 3 patients (3%): 1 with gastrointestinal perforation, which 
required surgery and 2 with gastrointestinal bleeding that did not require blood transfusion.  
 The log-rank test revealed that cumulative surgery-free survival was not affected in patients 
who were already on immunomodulators or anti-TNF at the onset of symptoms (Figure 3a, b), but was 
significantly lower in those who started immunomodulators or anti-TNF after the onset of symptoms 
(Figure 3c, d).  
 Multivariate analysis using Cox regression analysis showed that non-stricturing, non-
penetrating disease at onset, mild severity of symptoms, successful EBD, stricture length <2 cm, and 
initiation of immunomodulator or anti-TNF antibody after the onset of obstructive symptoms were 
associated with avoiding the need for intestinal resection (Table 2).  
 
Factors associated with intestinal resection after initial EBD 


































































resection or repeated EBD. Therefore, we examined the factors associated with outcomes after initial 
EBD. To include EBD interval as a factor for analysis, we excluded patients with a <1-year follow-up 
(Figure 1). The background characteristics of patients with successful EBD are shown in Suppl. Table 
1. Analysis using the Cox proportional hazard model revealed that severity of symptoms, EBD 
diameter, location of stricture, and interval of EBD were associated with risk of intestinal resection in 
univariate analysis (Table 3). Multivariate analysis revealed that longer interval of EBD was strongly 
associated with reduced risk of subsequent intestinal resection (Table 3). 
 
Factors associated with EBD interval after initial EBD 
Successful initial EBD does not always lead to better quality of life than surgery if symptoms recur 
and repeated EBD is required. Therefore, we analyzed the EBD interval, which predicts subsequent 
surgery, and we also analyzed factors associated with EBD interval. ROC analysis revealed a cutoff 
EBD interval of 446 days (AUC 0.750). Thus, we compared patients with an interval of ≤446 days 
between the initial and next EBD (patients with frequent EBD) and those with an interval of >446 
days (patients with less frequent EBD) (Suppl. Table 2). Logistic multivariate regression of the patients’ 
background characteristics showed more patients with a history of smoking among those with frequent 






































































This study revealed cumulative surgery-free survival in CD patients with surgically untreated 
symptomatic small bowel stricture was 74.0% at 1 year, 54.4% at 5 years, and 44.3% at 10 years. In 
successful EBD cases, cumulative surgery-free survival was 93.8%, 72.8%, and 62.9%, respectively. 
The factors associated with avoiding the need for intestinal resection were non-stricturing, non-
penetrating disease at onset, mild severity of symptoms, successful EBD, stricture length <2 cm, and 
immunomodulator or anti-TNF antibody therapy added after the onset of obstructive symptoms. After 
initial EBD, longer interval of EBD might reduce the risk of intestinal resection. It is also suggested 
that surgery is likely with a dilatation interval of ≤446 days and that the response to EBD was shown 
to be lower in patients who currently smoked.  
Approximately a quarter of CD patients with surgically untreated symptomatic small bowel 
stricture underwent intestinal resection within 1 year after onset of obstructive symptoms and 
approximately half underwent surgery 5 years later. A retrospective study comparing EBD with 
surgery for ileocolonic anastomotic stricture showed that the surgery rate was lower in patients for 
whom the initial intervention was surgery, but the time to surgery was extended by 6.45 years in 
patients for whom the initial intervention was EBD; the complication rate was lower with EBD than 
with surgery (1% vs 8%).24 Given concern about postoperative complications, EBD would be the 
better option when feasible. 
The severity of obstructive symptoms was also associated with intestinal resection. Pellietier 
et al. reported the efficacy of infliximab in patients with symptomatic Crohn’s disease strictures.4 They 
included patients with spontaneously self-limited obstruction, cramping abdominal pain, and complete 
obstruction. However, they did not show any differences in treatment efficacy in terms of prior 
symptoms. In the CREOLE study, the Crohn’s disease obstructive score (CDOS) was constructed 


































































the clinical-radiological prognostic score as independent factors associated with a high rate of 
success.9 Therefore, a CDOS>4 (i.e., severe abdominal pain for >1 week, mild to moderate abdominal 
pain every day that was associated with nausea, vomiting, abdominal cramps for >3 days or 
hospitalization during the previous 8 weeks) was a predictive factor for successful adalimumab 
treatment. Their results partially conflict with ours, but a simple comparison of the results is not 
possible because of the different evaluation methods used. Furthermore, the severity of symptoms 
alone cannot distinguish whether the stenosis is caused by inflammation or fibrosis. 
The success rate of EBD in this study was slightly lower than that of previous reports.16, 21, 
25, 26 These data seem to reflect the real-world situation as this cohort includes cases from institutions 
that are not actively performing EBD. The cumulative surgery-free survival in successful EBD cases 
in the present study was as high as reported previously,20, 21, 27 suggesting the utility of EBD for small 
bowel stricture. Fistula at the stricture site,20 unsuccessful EBD,21 stricture size ≥2 cm,22 extent of 
small bowel dilatation proximal to the stricture,22 and presence of ≥2 strictures27 have been reported 
to be surgery-associated factors in patients who have undergone BAE. The present study confirmed 
an association between unsuccessful EBD and stricture length ≥2 cm, but not an association between 
the number of strictures and surgery. Patients with fistula were not included, and the extent of small 
bowel dilatation proximal to the stricture was not examined in this study. 
A population-based study revealed that surgery is performed less often for CD with the 
current availability of immunomodulator and biologic agents.28 This study revealed that cumulative 
surgery-free survival was higher in patients with non-stricturing, non-penetrating disease at onset. 
Given that patient enrollment started in 2008 in this study, medication such as immunomodulators and 
anti-TNF antibody might have suppressed the progression of fibrosis at stricture site.  
This study found that the intestinal resection rate was lower when immunomodulator or anti-


































































mentioned earlier, the effect of immunomodulator or anti-TNF antibody in CD with stricture is 
controversial. Findings from the CREOLE study showed that enhancement on delayed T1-weighted 
magnetic resonance imaging sequences is a factor associated with avoiding the need for surgery,9 
suggesting that anti-TNF antibody is effective for inflammatory stricture. However, distinguishing 
fibrotic from inflammatory stricture is difficult based on imaging findings alone. Given the results of 
this study, immunomodulator or anti-TNF antibody therapy should be considered for CD patients with 
a small bowel stricture.  
The most relevant factor contributing to intestinal resection after successful initial EBD was 
the EBD interval. The need for repeated EBD is a clinical challenge. Repeated EBD reduces quality 
of life. This study found an association between an EBD interval of ≥446 days and intestinal resection. 
Unlike patients with ulcerative colitis, patients with CD do not require regular endoscopic surveillance. 
In patients who underwent EBD within 466 days (a little over 1 year), it was suggested that some 
gastrointestinal symptoms might have been present and that periodic EBD may be required. Also, 
repeat EBD was required in patients with a history of smoking, indicating the importance of guidance 
on smoking cessation. Hirai et al. reported that the amelioration of symptoms is related to the 
maximum diameter of EBD; however, the observation period was short (4 weeks) and information on 
smoking history was not stated.16  
There are some limitations to this study. First, interventions for small bowel stricture varied 
among the participating institutions. The choice of treatment, such as EBD or surgery, was dependent 
on the treatment strategy of each institution. Therefore, it is possible that some patients who did not 
have EBD performed chose surgery by themselves. Besides, our results may be affected by imbalances 
between participating institutions. Second, attending physicians usually decide the treatment of choice 
(e.g., the indication for EBD or scheduled maintenance of EBD, and when to initiate anti-TNF 


































































performed in the first place, which may affect the prognostic analysis. Also, some facilities might have 
scheduled maintenance EBD after the first EBD. Although this study investigated the effect of anti-
TNF antibody on avoiding the need for surgery, we cannot exclude the possibility that factors other 
than patient characteristics included in multivariate analysis are affected. In terms of the treatment, we 
did not investigate the status of enteral nutrition therapy. Enteral nutrition may delay the surgery, but 
its long-term efficacy is not proven.29 In a systematic review, it was shown that enteral nutrition may 
be less efficacious than corticosteroids in the induction of remission in adult patients with CD.30 Third, 
we used an ICD-10 code search or a search of records in the institutional databases such as the 
endoscopy filing systems, as a screening tool to extract eligible patients. We evaluated individual 
candidates by checking the medical chart to determine whether they actually had obstructive 
symptoms and were eligible to participate in this study. The severity of symptoms was evaluated from 
the medical charts and findings of imaging examinations such as CT, MRI, and small bowel follow-
through. Therefore, there might be some omissions in identifying cases at each institution. Also, there 
might be uncertain factors regarding the assessment of symptom severity. Fourth, this study includes 
symptomatic patients only, so the efficacy of prophylactic EBD could not be clarified. Fifth, stricture 
site was divided into two types, ileocecal valve and small intestinal strictures, in this study because 
this was a retrospective study and we did not collect information about the distance from the ileocecal 
valve to the stricture. Therefore, some strictures in the lower ileum may be easily accessed with a 
colonoscope. Sixth, the patient population in this study comprised rare cases, which are unlikely to be 
included in a randomized controlled study, and therefore data on a larger number of patients are needed 
in the future.  
In summary, this study revealed the factors associated with cumulative surgery-free survival 
in CD patients with symptomatic small bowel stricture. To avoid intestinal resection, patients who 


































































for EBD and anti-TNF antibody therapy even after the onset of obstructive symptoms. EBD is an 
important procedure in avoiding intestinal resection. Thus, to maximize the effect of EBD, dilatation 
should be performed with a diameter of ≥15 mm. In addition, smoking cessation should be encouraged 
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Table 1. Background characteristics of the patients 
Characteristic EBD performed EBD not performed Total P value* 
Number of patients 100 205 305 - 
Age at disease onset (years), 
median (IQR) 
26.5 (21.3-35.4) 27.3 (21.3-35.6) 26.7 (21.5-35.5) 0.625a 
Age at obstructive symptom onset 
(years), median (IQR) 
35.2 (27.5-42.4) 34.8 (25.8-42.7) 34.9 (26.4-42.7) 0.566a 
Disease duration (years), median 
(IQR) 
4.8 (0.5-10.5) 2.7 (0.1-9.9) 3.1 (0.2-10.1) 0.067a 
Sex (male/female) 77/23 149/56 226/79 0.503b 
Disease location 
(ileal/ileocolonic) 
51/49 124/81 175/130 0.147b 
Disease behavior (non-stricturing, 
non-penetrating/stricturing) 
47/53 87/118 134/171 0.528b 
Perianal disease (present/absent) 39/61 69/136 108/197 0.431b 
Smoking (never/previous/current) 70/11/19 150/23/32 220/34/51 0.756b 
Obstructive symptoms 
(mild/moderate/severe) 
24/17/193 35/36/134 59/53/193 <0.001b 
Endoscope used to approach 
stricture (colonoscope/BAE/not 
performed) 
13/87/0** 52/94/59† 65/181/59 <0.001b 
Location of strictures (small 
intestine/ileocecal valve) 
87/13 176/29 263/42 0.924b 
Number of strictures 
(single/dual/multiple) 
44/24/32 98/30/77 142/54/109 0.127b 
Stricture length (<2 cm/≥2 cm) 90/10 125/80 215/90 <0.001b 
Intestinal resection during 
observation period (yes/no) 


































































Reason for intestinal resection 
(stricture/perforation/abscess/EBD 
complication) 
21/2/0/2 99/4/1/0 120/6/1/2 0.022b 
Observation period (days), median 
(IQR) 




37/38/25 122/46/37 159/84/62 <0.001b 
Biologics use (never/before 
symptoms/after symptoms) 
37/31/32 100/43/62 137/74/94 0.085b 
IQR: interquartile range; EBD: endoscopic balloon dilatation; BAE: balloon-assisted enteroscope 
*Comparison between EBD performed and EBD not performed. 
**Details of the scope are as follows: conventional colonoscope/thin colonoscope/long thin 
colonoscope/single-balloon enteroscope/double-balloon enteroscope/not performed = 7/1/5/41/46/0. 
†Details of the scope are as follows: conventional colonoscope/thin colonoscope/long thin 
colonoscope/single-balloon enteroscope/double-balloon enteroscope/not performed = 
39/7/6/52/42/59. 




































































Table 2. Factors associated with intestinal resection for all patients 
All patients (N = 305) Univariate HR (95% CI), 
p value 
Multivariate HR (95 %CI), 
p value 
Age at disease onset (years) 0.989 (0.973-1.005), 0.188 - 
Age at obstructive symptom 
onset (years) 
0.992 (0.977-1.007), 0.304 - 
Disease duration (years) 1.004 (0.981-1.026), 0.694 - 
Male 1.142 (0.759-1.719), 0.523 - 
Disease location (ileocolonic) 1.083 (0.764-1.535), 0.652 - 
Disease behavior (stricturing) 1.324 (0.929-1.888), 0.120 1.449 (1.001-2.116), 0.048 
Perianal disease 0.877 (0.607-1.268), 0.486 - 
Current or previous smoker 1.433 (0.992-2.067), 0.054 1.329 (0.898-1.940), 0.152 
Severity of symptoms   
    Mild 1.000 1.000 
    Moderate 2.281 (1.229-4.396), 0.086 2.032 (1.086-3.944), 0.026 
    Severe 2.142 (1.277-3.857), 0.003 1.963 (1.152-3.576), 0.018 
Endoscope used to approach stricture  
    BAE 1.000 1.000 
    Not performed 2.492 (1.634-3.800), <0.001 1.235 (0.752-2.006), 0.399 
    Colonoscopy 1.548 (1.012-2.367), 0.043 1.084 (0.680-1.699), 0.727 
Small intestinal stricture 0.825 (0.512-1.329), 0.429 - 
Number of strictures 1.029 (0.849-1.247), 0.770 1.079 (0.885-1.315), 0.446 
Long stricture (≥2 cm) 3.089 (2.182-4.373), <0.001 2.176 (1.477-3.201), <0.001 
Successful EBD 0.350 (0.226-0.543), <0.001 0.485 (0.294-0.779), 0.002 
Addition of immunomodulator 
after stenotic symptoms 


































































Addition of anti-TNF after 
stenotic symptoms 
0.599 (0.397-0.903), 0.014 0.612 (0.385-0.947), 0.036 
Univariate and multivariate analysis were conducted by Cox regression analysis. Bold indicates 
statistically significant results.  
HR: hazard ratio; CI: confidence interval; BAE: balloon-assisted enteroscopy; EBD: endoscopic 


































































Table 3. Factors associated with intestinal resection after initial EBD  
Patients (n = 95) Univariate OR (95% CI), 
p value 
Multivariate OR (95% CI), 
p value 
Age at obstructive symptom onset 
(years) 
0.992 (0.951-1.032), 0.701 - 
Disease duration (years) 0.996 (0.942-1.045), 0.908 - 
Male 0.802 (0.332-2.229), 0.644 - 
Disease location (ileocolonic) 1.091 (0.484-2.459), 0.830 - 
Disease behavior (stricturing) 0.848 (0.376-1.912), 0.687 - 
Perianal disease 0.620 (0.239-1.438), 0.287 - 
Current or previous smoker 1.093 (0.470-2.831), 0.843 - 
Severity of symptoms   
    Mild 1.000 1.000 
    Moderate 3.267 (1.027-12.255), 0.044 3.323 (0.956-13.389), 0.058 
    Severe 1.214 (0.420-4.356), 0.733 1.107 (0.367-4.087), 0.863 
BAE used to approach stricture 0.653 (0.246-2.252), 0.439 - 
Diameter of EBD (≥15 mm) 0.418 (0.161-0.969), 0.042 0.503 (0.189-1.211), 0.127 
Small intestinal stricture 0.281 (0.115-0.798), 0.019 0.564 (0.199-1.753), 0.307 
Number of strictures (≥2) 0.519 (0.222-1.167), 0.112 0.548 (0.207-1.429), 0.217 
Long stricture (≥2 cm) 1.414 (0.333-4.123), 0.575 1.679 (0.370-5.570), 0.459 
Addition of immunomodulator 
after symptomatic stricture 
1.049 (0.405-2.436), 0.914 - 
Addition of anti-TNF after 
symptomatic stricture 
0.805 (0.309-1.877), 0.631 - 
EBD interval (days) 0.996 (0.993-0.998), <0.001 0.997 (0.994-0.998), <0.001 
EBD: endoscopic balloon dilatation; OR: odds ratio; CI: confidence interval; BAE: balloon-assisted 






































































































































Table 4. Factors associated with EBD interval 
Patients (n = 95) Univariate OR (95% CI),  
p value 
Multivariate OR (95% CI), 
 p value 
Age at obstructive symptom 
onset (years) 
0.999 (0.959-1.042), 0.996 - 
Disease duration (years) 1.009 (0.958-1.062), 0.728 - 
Male 1.010 (0.375-2.620), 0.983 - 
Disease location (ileocolonic) 0.985 (0.430-2.257), 0.971 - 
Disease behavior (stricturing) 0.910 (0.395-2.082), 0.824 - 
Perianal disease 0.896 (0.385-2.084), 0.799 - 
Smoking status    
    Never 1.000 1.000 
    Previous 4.102 (0.964-28.295), 0.056 4.528 (0.883-23.215), 0.070 
    Current 3.419 (1.103-12.996), 0.032 3.606 (1.051-12.365), 0.041 
Severity of symptoms   
    Mild 1.000 - 
    Moderate 2.321 (0.581-9.260), 0.232 - 
Severe 0.962 (0.363-2.550), 0.939 - 
BAE used to approach stricture 0.659 (0.187-2.321), 0.509 - 
Diameter of EBD (≥15 mm) 0.769 (0.336-1.759), 0.534 - 
Small intestinal stricture 0.244 (0.050-1.172), 0.047 0.275 (0.054-1.396), 0.087 
Number of strictures (≥2) 0.874 (0.381-2.006), 0.751 - 
Long stricture (≥2 cm) 2.800 (0.560-13.987), 0.175 3.044 (0.569-16.292), 0.165 
Addition of immunomodulator 
after symptomatic stricture 
1.380 (0.522-3.649), 0.511 - 



































































Smoking status was analyzed on an ordinal scale ranging from never to current smoking. 




































































Figure 1. Study participants 
 
Figure 2. Cumulative surgery-free survival for all patients 
Kaplan-Meier curves depicting cumulative surgery-free survival for all patients (a), stratified by 
severity of symptoms (b), scope used to examine stricture (c), stricture length (d), and successful 
EBD (e). The stratified analysis of EBD, which was confined to patients who had undergone 
endoscopy (n = 246) is also shown (f). P values on each curve were calculated using the log-rank 
test.  
BAE: balloon-assisted enteroscopy; CS: colonoscopy; EBD: endoscopic balloon dilatation 
 
Figure 3. Administration of immunomodulators (IM) and anti-TNF agents and intestinal resection 
Kaplan-Meier curves for cumulative surgery-free survival stratified by presence of 
immunomodulator (a) or anti-TNF therapy (b) at the time of symptomatic stricture onset, and the 





































































Supplementary Table 1. Background characteristics of patients with successful EBD 
Characteristic n = 95 
Age at obstructive symptom onset (years), median (IQR) 34.9 (27.5-42.6) 
Disease duration (years) 5.3 (0.7-11.8) 
Sex (male/female) 72/23 
Disease location (ileal/ileocolonic) 46/49 
Disease behavior (non-stricturing, non-penetrating/stricturing) 45/50 
Perianal disease (present/absent) 37/58 
Smoking (never/previous/current) 65/11/19 
Obstructive symptoms (mild to moderate/severe) 40/55 
Endoscope used to approach stricture (colonoscope/BAE) 13/82 
Location of stricture (small intestine/ileocecal valve) 82/13 
Number of strictures (single/dual/multiple) 43/22/30 
Stricture length (<2 cm/≥2 cm) 85/10 
Diameter of EBD (<15 mm)/ ≥15 mm) 50/45 
Intestinal resection during observation period (yes/no) 24/71 
Observation period after initial EBD (days), median (IQR) 1135 (184-459) 
Addition of immunomodulator after symptomatic stricture (yes/no) 24/71 
Addition of anti-TNF after symptomatic stricture (yes/no) 27/68 
EBD interval (days), median (IQR) 332 (155-651) 
EBD: endoscopic balloon dilatation; IQR: interquartile range; BAE: balloon-assisted enteroscope; 







































































Supplementary Table 2. Comparison of background characteristics in patients with successful EBD 
according to the therapeutic response to initial EBD 
Patients (n = 95) Patients with less 
frequent EBD 
(n = 37) 
Patients with frequent 
EBD 
(n = 58) 
p value 
Characteristic    
Age at obstructive symptom onset 
(years), median (IQR) 
34.9 (26.2-42.8) 35.2 (29.1-41.0) 0.890 
Disease duration (years) 4.6 (0.3-13.0) 6.0 (0.7-10.2) 0.572 
Male/female 28/9 44/14 0.983 
Disease location (ileal/ileocolonic) 19/18 30/28 0.971 
Disease behavior (non stricturing, 
non-penetrating/stricturing) 
17/20 28/30 0.824 
Perianal disease (present/absent) 15/22 22/36 0.799 
Smoking (never/previous/current) 31/2/4 34/9/15 0.029 
Obstructive symptoms 
(mild/moderate/severe) 
10/23/4 14/31/13 0.333 
Scope used to approach stricture 
(BAE/colonoscope) 
33/4 49/9 0.509 
Diameter of EBD (<15 mm/≥15 mm) 18/19 32/26 0.534 
Location of stricture (small 
intestine/ileocecal valve) 
35/2 47/11 0.047 
Number of strictures (single/dual or 
multiple) 
16/21 27/31 0.751 
Length of stricture (<2cm/≥2 cm) 35/2 50/8 0.175 
Addition of immunomodulator after 
symptomatic stricture (yes/no) 
8/29 16/42 0.511 
Addition of anti-TNF after 
symptomatic stricture (yes/no) 


































































Follow-up information and outcomes 
Number of EBDs performed during 
observation period, median (IQR) 
1 (0-2) 3 (1-4) <0.001 
EBD interval (days), median (IQR) 813 (586-1546) 173 (120-316) <0.001 
Observation period, median (IQR) 1943 (1667-2692) 764 (416-1695) <0.001 
Intestinal resection (yes/no) 2/35 22/36 <0.001 
Patients with less frequent EBD indicate patients with an interval of >446 days between the initial 
and next EBD, and patients with frequent EBD indicate those with an interval of ≤446 days.   
EBD: endoscopic balloon dilatation; IQR: interquartile range; BAE: balloon-assisted enteroscope; 





































































Figure legends for supplementary figures 
Supplementary Figure 1. Cumulative surgery-free survival for all patients 
Kaplan-Meier curves depicting cumulative surgery-free survival for all patients stratified by sex (a), 
disease location (b), disease behavior (c), perianal lesion (d), smoking (e), location of stricture (f), 
number of strictures (g). P values on each curve were calculated using the log-rank test.  
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